Three Way Takeover Battle: Mylan to list on TASE if Perrigo bid succeeds


(L-R) Robert J Coury,   Mylan and Josegh Papa,   Periggo


One of the main worries of Tel Aviv Stock Exchange (TASE) leaders recently has been the expected delisting of Perrigo Company (NYSE:PRGO; TASE:PRGO), if and when the company’s acquisition by Mylan Pharmaceuticals is completed.

Perrigo has been listed on the TASE for a decade (since it acquired Israeli company Agis), and it constitutes a considerable part of the Tel Aviv 25 index, in addition to being listed on the New York Stock Exchange. With a $27.6 billion market cap, Perrigo accounts for 9.8% of the index, putting it in third place behind Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Bank Leumi (TASE: LUMI).

The acquisition of the company and the delisting of its share are liable to significantly shrink trading volumes on the TASE, which in any case has been rather moribund in recent years…

Continue reading


GLOBES logo-eng (1) Published by Globes [online], Israel business news –


TEVA ,   EREZ VIGODMAN Robert-J-Coury-1 Mylan 320X=p

By Niva Goldberg On Thursday, May 28th, 2015

Three Way Takeover Battle: Teva Doesn’t Take NO as an Answer

Teva Pharmaceutical Industries Ltd, an Israeli-based company, has acquired a 1.35 percent stake in Mylan through purchases on the open market, increasing pressure on its rival’s management to come to the More…

(L-R) Robert J Coury,   Mylan and Josegh Papa,   Periggo

By Koby Yeshayahou On Tuesday, May 12th, 2015

Three Way Takeover Battle: Mylan Mulling Improved Offer for Perrigo – Bloomberg

Mylan (MYL) is considering an improved offer to shareholders of Perrigo (PRGO) with the aim of acquiring the company and thus heading off the hostile bid for Mylan from Teva Pharmaceutical Industries Ltd. (NYSE: More…

(L-R) Robert J Coury,   Mylan and Josegh Papa,   Periggo

By Pittsburgh Post-Gazette On Thursday, May 7th, 2015

Perrigo Backs Reason to Spurn Mylan

When Mylan and Perrigo executives had a “very preliminary” discussion a year ago about possibly merging the two generic drug companies, Perrigo was a different company, according to its CEO Joe Papa. Back More…

(L-R) Robert J Coury,   Mylan and Josegh Papa,   Periggo

By Globes On Wednesday, April 29th, 2015

Perrigo Again Rejects Improved Mylan Offer

Mylan offered Perrigo shareholders $75 plus 2.3 Mylan shares per Perrigo share, for a total of $35.6 billion. Perrigo Company (NYSE:PRGO; TASE:PRGO) board of directors has rejected Mylan’s improved offer. Mylan More…

(L-R) Robert J Coury,   Mylan and Josegh Papa,   Periggo

By Globes On Wednesday, April 29th, 2015

Mylan Raises Offer to Buy Perrigo to $35.6 Billion

Mylan, itself the subject of a hostile takeover bid from Teva, is raising its offer for Perrigo for the second time. Mylan N.V. has for the second time raised its offer to buy US-Irish-Israeli generic pharmaceuticals More…



Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.